Kyverna Therapeutics
- Est. revenue
- $10M–$20M
- Total raised
- $295M
- Latest round
- Post-IPO Equity
- Employees
- 177
Funding & revenue at Kyverna Therapeutics
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$10M–$20M
Modeled range, not company-reported
Total capital raised
$295M
18 known investors
Latest round
Post-IPO Equity · $100M
Dec 2025
Publicly traded
KYVERNATHERAPEUTICS, KYTX
IPO Feb 2024
Investors
Growth signals
How fast Kyverna Therapeutics is adding people, roles, and audience.
Employees
177
Reported band 51-200
LinkedIn followers
47.9K
+94% year over year
Headcount change
- MoM
- +5.4%
- +9 people
- QoQ
- +7.9%
- +13 people
- 6mo
- +14.2%
- +22 people
- YoY
- +20.4%
- +30 people
- 2yr
- +30.1%
- +41 people
Team composition
Where Kyverna Therapeutics concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research3520%
- Business Development2313%
- Operations1911%
- Quality Assurance169%
- Information Technology137%
- Human Resources85%
- Healthcare Services85%
- Legal63%
By region
- United States167
- California, United States108
- San Francisco Bay Area75
- Los Angeles Metropolitan Area26
- San Francisco, CA19
- Emeryville, CA11
Inside Kyverna Therapeutics
What the business focuses on, where it operates, and how employees rate it.
Specialties
Categories
Markets
Competitors
Companies in the same market as Kyverna Therapeutics.
Kyverna Therapeutics in the news
Recent coverage picked up alongside the firmographic refresh.
- What Explains the 5.34% Premarket Gain for Kyverna (NASDAQ:KYTX) on Oct 9?
Oct 2026
- Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Oct 2026
- Kyverna Therapeutics (Nasdaq:KYTX) - Stock Analysis
Oct 2026
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Oct 2026
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Oct 2026
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Sep 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed October 16, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Kyverna Therapeutics, you can claim this page to manage and enhance it.